Cartesian Therapeutics, Inc. Revenue Not from Contract with Customer
Cartesian Therapeutics, Inc. (RNAC) reported Revenue Not from Contract with Customer of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RevenueNotFromContractWithCustomer · last filed 2026-08-06
- Cartesian Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Cartesian Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2026-03-31 was $78.00K, a 88.86% decline year-over-year.
- Cartesian Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2025-12-31 was $947.00K, a 1129.87% increase year-over-year.
- Cartesian Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2025-09-30 was $452.00K, a 16.80% increase year-over-year.
- Cartesian Therapeutics, Inc. revenue not from contract with customer for fiscal 2025 was $2.40M, a 275.71% increase from fiscal 2024.
- Cartesian Therapeutics, Inc. revenue not from contract with customer for fiscal 2024 was $638.00K.
- Cartesian Therapeutics, Inc. revenue not from contract with customer for fiscal 2023 was $0.00.
| Period end | Revenue Not from Contract with Customer 3 month | Revenue Not from Contract with Customer 6 month | Revenue Not from Contract with Customer 9 month | Revenue Not from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $78.00K 10-Q · filed 2026-08-06 | $1.02M derived: sum of 3 quarters · filed 2026-08-06 | $1.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $78.00K 10-Q · filed 2026-04-30 | $1.02M derived: sum of 2 quarters · filed 2026-04-30 | $1.48M derived: sum of 3 quarters · filed 2026-04-30 | $1.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $947.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.40M derived: sum of 2 quarters · filed 2026-03-09 | $1.70M derived: sum of 3 quarters · filed 2026-08-06 | $2.40M 10-K · filed 2026-03-09 |
| 2025-09-30 | $452.00K 10-Q · filed 2025-11-06 | $750.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.45M 10-Q · filed 2025-11-06 | $1.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $298.00K 10-Q · filed 2026-08-06 | $998.00K 10-Q · filed 2026-08-06 | $1.07M derived: sum of 3 quarters · filed 2026-08-06 | $1.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $700.00K 10-Q · filed 2026-04-30 | $777.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.16M derived: sum of 3 quarters · filed 2026-04-30 | $1.34M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $464.00K derived: sum of 2 quarters · filed 2026-03-09 | $638.00K derived: sum of 3 quarters · filed 2026-03-09 | $638.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $387.00K 10-Q · filed 2025-11-06 | $561.00K derived: sum of 2 quarters · filed 2025-11-06 | $561.00K 10-Q · filed 2025-11-06 | $561.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $174.00K 10-Q · filed 2025-08-07 | $174.00K 10-Q · filed 2025-08-07 | $174.00K derived: sum of 3 quarters · filed 2025-08-07 | $174.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-05-08 | $0.00 derived: sum of 3 quarters · filed 2025-05-08 | $0.00 derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |